Threshold Pharmaceuticals (THLD) Global Agreement with Merck KGaA

Social
Share

0 (0 Likes / 0 Dislikes)

Embed Video
Embed normal player Copy to Clipboard
Embed a smaller player Copy to Clipboard
Advanced Embedding Options
Embedding Options

Size:

Language:

Embed Code

Copy to Clipboard
Invite a user to Dotsub

Your invitation to join Dotsub was successful

There was an error inviting that user to Dotsub

Video Details

Duration: 1 minute and 34 seconds

Country: United States

Language: English

License: CC - Attribution No Derivatives

Genre: News Broadcast

Posted by: karmastock on Feb 4, 2012

Threshold Pharmaceuticals Inc - THLD - reported that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. Threshold will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012.

Report this video as offensive

Threshold Pharmaceuticals (THLD) Global Agreement with Merck KGaA

Embed Video

Video Details

Caption and Translate

Other videos from karmastock

CRWENewswire CEO Interviews: Alan Stone & Company, LLC

(DAVE, CRWE, ROYL) CRWENewswire Stocks to Watch